ClinConnect ClinConnect Logo
Search / Trial NCT01713959

Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis

Launched by ULTHERA, INC · Oct 22, 2012

Trial Information

Current as of May 17, 2025

Completed

Keywords

Underarm Sweating

ClinConnect Summary

Subjects will be randomized to one of two study groups:

* Group A: Split body treatment. Ultherapy to one axilla, Sham treatment to the other axilla.
* Group B: Bilateral Ultherapy treatments, with a pre-treatment subcutaneous lidocaine injection administered to one axillary side.

Hyperhidrosis Disease Severity Scale (HDSS), gravimetric test and starch iodine test will be obtained at all study visits. Patient satisfaction questionnaires will also be obtained at 30, 60 and 90 days post-treatment #2.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and female, ages 18-75
  • Subject is in good health
  • Diagnosis of bilateral axillary hyperhidrosis refractory to previous topical therapies
  • At least 50 mg of spontaneous resting axillary sweat production in each axilla measured gravimetrically at room temperature/humidity (20 - 25.6°C/20-80%) over a period of 5 minutes. (Patients should be at rest for at least 30 minutes after physical exercise including walking.)
  • HDSS score of 3 or 4.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Exclusion Criteria:
  • Dermal disorder including infection at anticipated treatment sites in either axilla.
  • Previous botulinum toxin treatment of the axilla in the past year.
  • Expected use of botulinum toxin for the treatment of any other disease during the study period.
  • Known allergy to starch powder or iodine.
  • Secondary hyperhidrosis, for example, hyperhidrosis that is secondary to other underlying diseases including hyperthyroidism, lymphoma and malaria.
  • Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage and ultrasonic surgery.
  • Women who are pregnant, lactating, possibly pregnant or planning a pregnancy during the study period.

About Ulthera, Inc

Ulthera, Inc. is a leading medical technology company specializing in non-invasive ultrasound solutions for aesthetic and therapeutic applications. Committed to advancing patient care through innovative research and development, Ulthera focuses on delivering safe and effective treatments that enhance skin lifting and tightening. The company’s flagship product, the Ultherapy system, utilizes ultrasound energy to stimulate collagen production and improve skin elasticity. By partnering with clinical researchers and practitioners, Ulthera aims to expand the understanding of ultrasound technology in dermatology and cosmetic procedures, ensuring high standards of safety and efficacy in all its offerings.

Locations

Aventura, Florida, United States

Patients applied

0 patients applied

Trial Officials

Mark Nestor, MD, Ph.D

Principal Investigator

The Center for Clinical & Cosmetic Research

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials